Economic Barriers in the Treatment of Clostridium difficile Infection With Oral Vancomycin

被引：20

作者：

Bunnell, Kristen L. ^{[1
]}

Danziger, Larry H. ^{[1
]}

Johnson, Stuart ^{[2
,3
]}

机构：

[1] Univ Illinois, Coll Pharm, Chicago, IL USA

[2] Edward Hines Jr VA Hosp, 5000 S,5th Ave Bldg 1, Hines, IL 60141 USA

[3] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA

来源：

OPEN FORUM INFECTIOUS DISEASES | 2017年 / 4卷 / 02期

关键词：

Clostridium difficile; pharmaceutical costs; vancomycin; HIGH-COST; DRUGS;

D O I：

10.1093/ofid/ofx078

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Vancomycin is an increasingly important option for the treatment of Clostridium difficile infection, but economic barriers to its use remain significant in the outpatient setting. Generic vancomycin capsules are still inexplicably expensive and not universally covered by insurers. This report highlights the potential adverse consequences of cost-related nonadherence to vancomycin therapy and the challenges that clinicians face when prescribing oral vancomycin.

引用

页数：3

共 15 条

[1] High-Cost Generic Drugs - Implications for Patients and Policymakers [J].